NASDAQ:PCVX

Vaxcyte Stock Forecast, Price & News

$25.36
-1.01 (-3.83 %)
(As of 09/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$25.27
$26.55
50-Day Range
$20.26
$26.97
52-Week Range
$15.51
$58.47
Volume1.13 million shs
Average Volume159,187 shs
Market Capitalization$1.32 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.49
30 days | 90 days | 365 days | Advanced Chart
Receive PCVX News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxcyte and its competitors with MarketBeat's FREE daily newsletter.


Vaxcyte logo

About Vaxcyte

Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops novel vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting Porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in Foster City, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.66 out of 5 stars

Medical Sector

937th out of 1,350 stocks

Biological Products, Except Diagnostic Industry

147th out of 193 stocks

Analyst Opinion: 0.0Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Vaxcyte (NASDAQ:PCVX) Frequently Asked Questions

What stocks does MarketBeat like better than Vaxcyte?

Wall Street analysts have given Vaxcyte a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Vaxcyte wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Vaxcyte's next earnings date?

Vaxcyte is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Vaxcyte
.

How were Vaxcyte's earnings last quarter?

Vaxcyte, Inc. (NASDAQ:PCVX) posted its quarterly earnings results on Wednesday, August, 11th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.52) by $0.06.
View Vaxcyte's earnings history
.

Who are Vaxcyte's key executives?

Vaxcyte's management team includes the following people:
  • Mr. Grant E. Pickering, Co-Founder, CEO & Director (Age 53, Pay $750.92k) (LinkedIn Profile)
  • Mr. Andrew L. Guggenhime M.B.A., Pres & CFO (Age 53, Pay $540.71k)
  • Mr. James Wassil M.B.A., M.S., Chief Operating Officer (Age 52, Pay $651.06k)
  • Dr. Ashish Khanna M.B.A., Ph.D., Co-Founder and Chief Bus. Officer (Age 49)
  • Dr. Jeff Fairman, Co-Founder & VP of Research (Age 57)
  • Kayo Chih, Sr. Accounting Mang.
  • Ms. Jane Wright-Mitchell J.D., Pharm.D., Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 52)
  • Mr. Paul W. Sauer M.B.A., MBA, Sr. VP of Process Devel. & Manufacturing (Age 59)

Who are some of Vaxcyte's key competitors?

What other stocks do shareholders of Vaxcyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxcyte investors own include NVIDIA (NVDA), Twilio (TWLO), The Boeing (BA), Overstock.com (OSTK), Pure Storage (PSTG), QUALCOMM (QCOM), Riot Blockchain (RIOT), American Tower (AMT), Avid Technology (AVID) and CalAmp (CAMP).

When did Vaxcyte IPO?

(PCVX) raised $210 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 14,000,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and Evercore ISI served as the underwriters for the IPO and Cantor and Needham & Company were co-managers.

What is Vaxcyte's stock symbol?

Vaxcyte trades on the NASDAQ under the ticker symbol "PCVX."

Who are Vaxcyte's major shareholders?

Vaxcyte's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), Vanguard Group Inc. (5.54%), BlackRock Inc. (4.57%), State Street Corp (2.88%), Geode Capital Management LLC (1.01%) and Ikarian Capital LLC (0.86%). Company insiders that own Vaxcyte stock include Grant Pickering, Group Holdings (Sbs) Advis Tpg, Jane Wright-Mitchell, Jeff Fairman, Jim Wassil, Paul Sauer, Ra Capital Healthcare Fund Lp, Ra Capital Management, LP and Robert Lorne Hopfner.
View institutional ownership trends for Vaxcyte
.

Which institutional investors are selling Vaxcyte stock?

PCVX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Sabby Management LLC, Ikarian Capital LLC, JPMorgan Chase & Co., Rafferty Asset Management LLC, Millennium Management LLC, Citigroup Inc., and Boothbay Fund Management LLC. Company insiders that have sold Vaxcyte company stock in the last year include Grant Pickering, Group Holdings (Sbs) Advis Tpg, Jane Wright-Mitchell, Jeff Fairman, Jim Wassil, Paul Sauer, Ra Capital Healthcare Fund Lp, Ra Capital Management, LP, and Robert Lorne Hopfner.
View insider buying and selling activity for Vaxcyte
or view top insider-selling stocks.

Which institutional investors are buying Vaxcyte stock?

PCVX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Ghost Tree Capital LLC, Geode Capital Management LLC, Vanguard Group Inc., Northern Trust Corp, Nuveen Asset Management LLC, Employees Retirement System of Texas, and Charles Schwab Investment Management Inc..
View insider buying and selling activity for Vaxcyte
or or view top insider-buying stocks.

How do I buy shares of Vaxcyte?

Shares of PCVX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vaxcyte's stock price today?

One share of PCVX stock can currently be purchased for approximately $25.36.

How much money does Vaxcyte make?

Vaxcyte has a market capitalization of $1.32 billion. The company earns $-89,220,000.00 in net income (profit) each year or ($3.02) on an earnings per share basis.

How many employees does Vaxcyte have?

Vaxcyte employs 58 workers across the globe.

What is Vaxcyte's official website?

The official website for Vaxcyte is www.vaxcyte.com.

Where are Vaxcyte's headquarters?

Vaxcyte is headquartered at 353 HATCH DRIVE, FOSTER CITY CA, 94404.

How can I contact Vaxcyte?

Vaxcyte's mailing address is 353 HATCH DRIVE, FOSTER CITY CA, 94404. The company can be reached via phone at 650-837-0111.


This page was last updated on 9/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.